Printer Friendly

TOPOX ANNOUNCES COMPLETION OF RECENT PRIVATE PLACEMENT AND ACCEPTANCE TO LIST ON EMERGING COMPANY MARKETPLACE

 TOPOX ANNOUNCES COMPLETION OF RECENT PRIVATE PLACEMENT
 AND ACCEPTANCE TO LIST ON EMERGING COMPANY MARKETPLACE
 CHADDS FORD, Pa., March 13 /PRNewswire/ -- Topox, Inc. announced today it has been accepted for trading on the American Stock Exchange Emerging Company Marketplace.
 Topox management said it feels privileged to be one of the select few companies that comprise this initial listing. The company said it believes this listing on the AMEX will significantly increase the level of exposure for its unique medical technologies. Trading will begin on Wednesday, March 18. The trading symbol will be TPO.EC.
 The company's recent funding efforts have increased gross assets to $3.1 million and shareholders' equity to $2.4 million (unaudited) as of March 12, 1992.
 Topox, Inc., designs, develops and markets proprietary medical products designed to diagnose, monitor, and heal a variety of skin disorders such as wounds, diabetic ulcerations, burns, pre-cancerous and cancerous lesions. These non-invasive technologies are safe, effective and easily tolerated by patients.
 /delval/
 -0- 3/13/92
 /CONTACT: James McGonigle, president of Topox, 800-38-TOPOX/
 (TPO.EC) CO: Topox, Inc. ST: Pennsylvania IN: MTC SU:


JS-MP -- PH025 -- 7878 03/13/92 14:40 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 13, 1992
Words:192
Previous Article:PATRICIA SAIKI, ADMINISTRATOR OF THE U.S. SMALL BUSINESS ADMINISTRATION ISSUES STATEMENT FROM WASHINGTON, D.C.
Next Article:GM ANNOUNCES CUSTOMER-SATISFACTION CAMPAIGN
Topics:


Related Articles
TOPOX ISSUES ANNOUNCEMENTS
PHARMETICS COMPLETES PRIVATE PLACEMENT
PHARMETICS COMPLETES PRIVATE PLACEMENT
GEORGE J. STASEN JOINS TOPOX AS EXECUTIVE VICE PRESIDENT AND CHIEF OPERATING OFFICER
TOPOX REPORTS RESULTS FOR FISCAL YEAR ENDED MARCH 31, 1992
TOPOX ANNOUNCES RESULTS FOR THE FIRST QUARTER ENDED JUNE 30, 1992
TOPOX ANNOUNCES THE FDA HAS RULED FAVORABLY ON ITS 510K APPLICATION
TOPOX: AGREEMENT SIGNED TO MANUFACTURE INNOVATIVE MEDICAL DEVICES
TOPOX TO CHANGE NAME
Cytomedix completes stock placement.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters